Entry Detail



General Information

Database ID:exR0089672
RNA Name:hsa-miR-29a-3p
RNA Type:miRNA
Chromosome:chr7
Starnd:-
Coordinate:
Start Site(bp):130876748End Site(bp):130876769
External Links:hsa-miR-29a-3p



Disease Information

Disease Name:Preterm Birth
Disease Category:Urogenital Diseases and Pregnancy Complications
MeSH ID:D047928
Type:Diseases Category/Female Urogenital Diseases and Pregnancy Complications
Alias:Premature Birth//Birth, Premature//Births, Premature//Premature Births//Preterm Birth//Birth, Preterm//Births, Preterm//Preterm Births



Expression Detail

GEO ID:GSE106224
Description:Exosomal RNA may reflect placenta deficiencies and provide better biomarker in preterm birth
Experimental Design:Disease vs Control
Case Disease Type:Preterm Birth
Case Disease SubType:NA
Case Sample:Preterm Birth
Control Sample:Control
Number of Case:20
Number of Control:50
Number of Samples:70





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
AMER1
chrX
64185117
64205708
-
APH1A
chr1
150265399
150269580
-
APP
chr21
25880550
26171128
-
BIRC5
chr17
78214186
78225636
+
C1QTNF6
chr22
37180166
37199385
-
CALU
chr7
128739292
128773400
+
CREG1
chr1
167529117
167553805
-
FASN
chr17
82078338
82098294
-
GATAD2B
chr1
153789030
153923360
-
KLHDC3
chr6
43014103
43021298
+
KMT5C
chr19
55339853
55348121
+
MAZ
chr16
29806106
29811164
+
NASP
chr1
45583846
45618904
+
NMI
chr2
151270470
151289894
-
PITPNA
chr17
1517718
1562792
-
RNF138
chr18
32091874
32131561
+
RREB1
chr6
7107597
7251980
+
SH3GLB1
chr1
86704570
86748184
+
SP1
chr12
53380176
53416446
+
TET3
chr2
73986404
74108176
+
XPO6
chr16
28097979
28211920
-
ATP5F1B
chr12
56638175
56645984
-
RHOH
chr4
40191053
40246967
+
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0000018
chr1
15860731
15863309
+
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC007036.3
chr7
30157531
30159534
+
AC012146.1
chr17
5111468
5115004
+
AC018521.1
chr17
47945424
47981736
+
AL137129.1
chr14
61734138
61776260
+
AL355488.1
chr1
110370154
110373003
+
AL391244.1
chr1
1420245
1422691
+
AP001432.1
chr21
37221419
37237744
+
H19
chr11
1995176
2001470
-
MIR4458HG
chr5
8450701
8486930
+
MIR497HG
chr17
7015818
7019659
-
MIRLET7BHG
chr22
46053869
46113928
+
NEAT1
chr11
65422774
65445540
+
OIP5-AS1
chr15
41283990
41309737
+
TUG1
chr22
30969245
30979395
+
XIST
chrX
73820649
73852723
-
Display:



Experiment Detail

GEO ID:GSE106224
Sample Source:Blood
Source Fraction:Plasma
Platform:GPL18573
Method:NGS
Num of detected RNA Type:1
Num of detected RNAs of this Type:1522
Sample treatment protocol:Whole blood samples were centrifuged for 15 minutes at 2,000×g at 4°C to get plasma. EVs were isolated from 100 ul of plasma using size exclusion columns (iZON qEV, Cambridge MA) with de-gassed 1X PBS from a total of 22 selected samples, 11 from each group (Table 1). Eluate (~500 ul for each fraction) was collected in microfuge tubes individually. The protein contains and concentration for each fraction were assessed by protein gel electrophoresis and Bradford assay (BioRad, Hercules, CA).
RNA Extract protocol:RNA was isolated from all plasma samples, the 22 EV samples, and 22 corresponding EV-depleted fractions using miRNeasy Micro Kit (Qiagne, Germantown MD).
RNA library preparation protocol:Small RNA sequencing libraries were generated with a modified small RNAseq protocol (manuscript in preparation) that alleviates most of the adapter-miRNA ligation sequence bias problem.



Reference

PMID:29516617
Title:Extracellular vesicle RNAs reflect placenta dysfunction and are a biomarker source for preterm labour
Author:Fallen S, Baxter D, Wu X, Kim TK, Shynlova O, Lee MY, Scherler K, Lye S, Hood L, Wang K
Journal:J Cell Mol Med. 2018 May;22(5):2760-2773.
Description:We have used an improved small RNA library construction protocol and a newly developed size exclusion chromatography (SEC)-based EV purification method to gain a comprehensive view of circulating RNA in plasma and its distribution by analysing RNAs in whole plasma and EV-associated and EV-depleted plasma.